← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Carogen Corporation
Hamden, CT
$5,207,630
Total funding
4
Grants
Funding over time
peak $1.2M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,943,639 · 3
CDC$263,991 · 1
By mechanism
R44$4,418,929 · 1
R43$788,701 · 3
Investigators at Carogen Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV$1,140,300
R44 · FY2023 · DK
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV$954,675
R44 · FY2022 · DK
GMP MANUFACTURE OF CLINICAL GRADE THERAPEUTIC VACCINE FOR THE TREATMENT OF PATIENTS WITH CHRONIC HBV$939,695
R44 · FY2021 · DK
DEVELOPING MULTI-ANTIGEN VACCINE FOR THE TREATMENT OF CHRONIC HBV$768,496
R44 · FY2020 · DK
DEVELOPING MULTI-ANTIGEN VACCINE FOR THE TREATMENT OF CHRONIC HBV$615,763
R44 · FY2019 · DK
VLVs as platform for nucleic acid-based delivery:Combining therapeutic vaccine with shRNA-mediated PD-L1 blockade for the treatment of chronic hepatitis B virus$300,000
R43 · FY2020 · AI
PA-21-259, SBIR, Phase I, Self-Amplifying RNA Replicon-Based Platform for Generating Multivalent Influenza Vaccine$263,991
R43 · FY2022 · IP
Enhancing Immunogenicity of VLV-Based Vaccines for Treatment of Chronic HBV$224,710
R43 · FY2018 · DK